The most commonly sold CJC-1295 and ipamorelin protocol pairs a peptide that lasts several days with one that clears in about 2 hours. That duration mismatch is the design question most stacking charts never mention.
A legitimate CJC-1295 and ipamorelin protocol is defined less by the doses than by the three things around them: a baseline IGF-1 before the first injection, a prescribing physician, and a 90-day retest that titration follows. The two-pathway rationale is real. What the marketing skips is that no published human trial has tested this specific pairing, and the most common version carries a duration mismatch worth understanding before you start.
- CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days; ipamorelin clears in about 2 hours [1][4]
- The two-pathway rationale is supported in humans, but with GHRP-6, not ipamorelin. Applying it to this pair is extrapolation [5]
- No published or registered trial has tested CJC-1295 plus ipamorelin in humans
- A defensible protocol requires a baseline IGF-1, a prescriber, and a 90-day retest, not a fixed-ratio blend
- Ipamorelin sits on FDA’s safety-risk bulk substances list, and an advisory committee voted 0 to 12 against permitting it for compounding [7][8]
Why the Two Are Paired
CJC-1295 is a long-acting GHRH analog acting on the GHRH receptor. Ipamorelin is a growth hormone secretagogue acting on the ghrelin receptor. Because these are separate pathways converging on the same pituitary cells, stimulating both should release more GH than stimulating either alone.
The principle is demonstrated in humans, with a caveat. In normal subjects given GHRH and GHRP-6 separately and together, GH area under the curve was 686 for GHRH alone, 1787 for GHRP-6 alone, and 4111 for the combination, higher than the arithmetic sum [5]. That is genuine supra-additivity. It used GHRP-6, not ipamorelin, so applying the exact magnitude to this stack is an extrapolation.
What Each Peptide Brings
CJC-1295 with Drug Affinity Complex binds serum albumin and has an estimated half-life of 5.8 to 8.1 days [1]. A single dose raised mean plasma GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days [1]. It does not flatten pulsatility: a study built to test it found pulse frequency and magnitude unchanged while basal GH rose 7.5-fold [2]. What rises is the trough between pulses.
Ipamorelin was introduced as the first selective growth hormone secretagogue [4], releasing GH without raising cortisol or prolactin at doses far above its GH threshold. That selectivity is the reason it is preferred over older GHRPs. The data behind it comes from swine and rats, not humans, and its action is short, on the order of a couple of hours.
The Duration Mismatch Most Charts Skip
Here is the design problem. CJC-1295 with DAC acts for days. Ipamorelin acts for hours. Pairing a multi-day analog with a 2-hour secretagogue and calling it a synchronized nightly pulse does not describe what the two molecules do on that schedule.
The pairing that is pharmacologically coherent uses the short form. CJC-1295 without DAC, often equated with Mod GRF 1-29, is short-acting like the unmodified GHRH fragment that clears in roughly 4 minutes [6], so dosing it alongside ipamorelin at bedtime lines the two up in time. The catch is that the no-DAC form is essentially uncharacterized in peer-reviewed human literature [3], with no controlled clinical studies. So the coherent version is the less-studied one, and the better-studied with-DAC form is the mismatched one.
When a product is labeled CJC-1295, ask whether it is the with-DAC or no-DAC form. They behave completely differently on a daily protocol, and vendor labeling frequently blurs the two. The answer determines whether pairing it with ipamorelin at bedtime makes pharmacologic sense.
What a Legitimate Protocol Requires
Strip away the stacking-chart specifics and a defensible protocol comes down to sequence and measurement, not a fixed recipe.
- A baseline IGF-1 before the first injection, interpreted against the age-adjusted range. Skipping it is the first red flag
- A prescribing physician who sets the dose. Commonly used protocols pair 100 to 200 mcg of each at bedtime, but the number that matters is the one set against your IGF-1, not a template
- Monotherapy reasoning first: establish what a GHRH analog alone does to your IGF-1 before adding a second peptide, so you know which component drives which effect
- Separate vials rather than a fixed-ratio blend, so one peptide can be reduced without the other if IGF-1 overshoots
- A 90-day IGF-1 retest, with a result above the age-adjusted range treated as a reason to lower dose rather than continue
Red Flags in a Stack Protocol
- No baseline or follow-up IGF-1. Without measurement, nobody can tell whether the protocol pushed you above range
- A fixed-ratio blended vial, which makes it impossible to titrate one peptide independently
- No disclosure that FDA lists ipamorelin acetate among bulk substances that may present significant safety risks [8], or that its Pharmacy Compounding Advisory Committee voted 0 in favor and 12 against permitting it for compounding [7]
- Product sold under "research use only" labeling with no prescription, which is gray-market rather than compounded under a licensed pharmacy
- Enumerated CJC-1295 amino-acid substitution lists that only appear on vendor sites and disagree with each other
The Anti-Doping Line
Both peptides are prohibited in tested sport. The 2026 WADA Prohibited List names growth hormone releasing factors under section S2.2.4 [9], covering GHRH analogs like CJC-1295 and secretagogues like ipamorelin, prohibited at all times in and out of competition. For anyone subject to testing, this stack is disqualifying regardless of how it is dosed.
CJC-1295 with ipamorelin only makes sense against a baseline IGF-1 and a 90-day retest, run by a prescriber who can titrate each peptide. SystemLabs tests IGF-1 before prescribing and formulates GHRH-analog protocols on clinical indication through a licensed pharmacy, so the plan is built from your labs rather than a fixed-ratio vial.
Frequently Asked Questions
What is the CJC-1295 ipamorelin stack?
It pairs a long-acting GHRH analog, CJC-1295, with a selective growth hormone secretagogue, ipamorelin, to stimulate two pituitary pathways at once. The two-pathway rationale is supported in humans, but with GHRP-6 rather than ipamorelin [5], and no published trial has tested this specific combination. CJC-1295 with DAC has a half-life of 5.8 to 8.1 days [1] while ipamorelin clears in about 2 hours [4].
What is the correct CJC-1295 ipamorelin dosing?
There is no single correct dose, and that is the point. Commonly used protocols pair 100 to 200 mcg of each at bedtime, but the dose that matters is one a prescribing physician sets against your baseline IGF-1, then adjusts on a 90-day retest. A protocol that names a fixed dose without ever drawing an IGF-1 is optimizing convenience, not outcomes.
Should CJC-1295 be used with or without DAC alongside ipamorelin?
It depends on the schedule, and this is where most charts go wrong. CJC-1295 with DAC lasts several days [1], so pairing it with a 2-hour secretagogue for a nightly pulse is a mismatch. The no-DAC form is short-acting and lines up in time with ipamorelin, but it is essentially uncharacterized in human trials [3]. Confirm which form you are actually being dispensed.
How long does the CJC-1295 ipamorelin stack take to work?
IGF-1 responds quickly. A single CJC-1295 dose raised IGF-1 1.5 to 3-fold for 9 to 11 days [1], so a 90-day retest reliably captures the biochemical response. Body composition changes from GH-axis therapy develop over months rather than weeks, which is why a 6-month window is the honest timeline for judging outcomes.
Is the CJC-1295 ipamorelin stack legal and safe?
Neither peptide is an FDA-approved drug. FDA lists ipamorelin acetate among bulk substances that may present significant safety risks, and its advisory committee voted 0 to 12 against permitting it for compounding [7][8]. Both are prohibited in tested sport at all times [9]. Any use should run through a licensed prescriber with IGF-1 monitoring, not a research-chem vial.
What are the red flags in a CJC-1295 ipamorelin protocol?
No baseline or follow-up IGF-1, a fixed-ratio blended vial that cannot be titrated, no disclosure of ipamorelin’s FDA safety-risk listing or the 0-to-12 advisory vote [7][8], product sold as "research use only" without a prescription, and vendor substitution-list claims that only appear on sales pages. Any one of these is a reason to slow down.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 7962295. https://pubmed.ncbi.nlm.nih.gov/7962295/
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. FDA Category 2 bulk substances list. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
